Palboxen 125 mg (Palbociclib) Capsule


Palboxen 125 mg (Palbociclib) Capsule

Introduction to Palboxen 125 mg (Palbociclib)

Palboxen 125 , meticulously manufactured by Everest Pharma Ltd. and distributed by the dedicated efforts of Orio Pharma, represents a significant advancement in breast cancer treatment. With Palbociclib as its active ingredient, this medication symbolizes progress in precision medicine, providing new avenues of hope and efficacy for individuals battling advanced breast cancer.

Description and Usage: Palboxen 125 mg (Palbociclib)

Palboxen 125 is a targeted therapy intricately designed for the treatment of advanced or metastatic breast cancer. Palbociclib, the active component, is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6, which are crucial for cell division. By inhibiting these kinases, Palboxen effectively slows down the progression of cancer cells.

How Palboxen 125 mg Works

Palbociclib works by inhibiting CDK4 and CDK6, enzymes that are essential for the proliferation of cancer cells. By blocking these kinases, Palboxen 125 prevents cancer cells from progressing through the cell cycle, thereby slowing down their growth and spread. This targeted mechanism disrupts the cell cycle, leading to reduced tumor growth and improved patient outcomes.

Dosage and Administration

The prescribed dosage of Palboxen 125  is typically 125 taken orally once daily for 21 consecutive days, followed by a 7-day break. This 28-day cycle is repeated as advised by the healthcare professional. The treatment plan may vary based on individual patient factors, including overall health and the specifics of the cancer being treated. Regular monitoring and adjustments by healthcare professionals ensure optimal therapeutic outcomes.


In the evolving field of breast cancer treatment, Palboxen 125 emerges as a beacon of hope for individuals facing advanced stages of the disease. Its targeted mechanism, combined with the convenience of oral administration, signifies a significant leap forward in personalized medicine. This approach not only enhances treatment efficacy but also underscores a commitment to patient-centric care throughout their therapeutic journey.

Benefits of Palboxen 125 mg

  • Targeted CDK Inhibition: Palboxen 125 selectively inhibits CDK4 and CDK6, crucial enzymes for cancer cell proliferation, offering a targeted approach that minimizes damage to healthy cells.
  • Extended Progression-Free Survival: Clinical studies have demonstrated that Palboxen 125 significantly extends progression-free survival in patients with advanced breast cancer.
  • Improved Quality of Life: By effectively managing the growth of cancer cells, Palboxen 125 contributes to an improved quality of life for patients, allowing them to maintain a higher level of well-being during treatment.

Manufacturer: Everest Pharma Ltd.

The formulation and production of Palboxen 125 reflect the expertise and dedication of Everest Pharma Ltd. This pharmaceutical leader is committed to advancing healthcare through cutting-edge research and development, utilizing state-of-the-art manufacturing processes to ensure the consistency, safety, and efficacy of its products.

Supplier: Orio Pharma

In the pivotal role of distribution, Orio Pharma ensures that the benefits of Palboxen 125 reach healthcare providers and patients globally. Committed to excellence, Orio Pharma upholds stringent standards in the distribution process, ensuring timely and reliable access to Palboxen 125 for those in need.


The collaboration between Everest Pharma Ltd.’s manufacturing excellence and Orio Pharma’s commitment to distribution is instrumental in the success story of Palboxen 125 . Together, they contribute to the ongoing battle against advanced breast cancer, exemplifying the collaborative spirit that propels medical advancements and offers renewed hope to patients and their families.